Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership
Dec 11, 2024 11:06 HKT | |
|
雲頂新耀：加速腎病領域創新 邁向全球生物製藥領先地位
Dec 11, 2024 11:02 HKT | |
|
云顶新耀：加速肾病领域创新 迈向全球生物制药领先地位
Dec 11, 2024 10:56 HKT | |
|
VisiRose Introduces Revolutionary Therapy for Severe Eye Infections
Dec 10, 2024 20:30 HKT |  |
|
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
Dec 04, 2024 11:08 HKT |  |
|
雲頂新耀宣佈治療原發性膜性腎病的新型BTK抑制劑EVER001在1b/2a期臨床試驗階段性數據中取得積極結果
Dec 04, 2024 10:59 HKT | |
|
云顶新耀宣布治疗原发性膜性肾病的新型BTK抑制剂EVER001在1b/2a期临床试验阶段性数据中取得积极结果
Dec 04, 2024 10:48 HKT | |
|
康哲藥業獲得治療痛風及高尿酸血症的1類新藥獨家商業化權利
Dec 02, 2024 20:49 HKT |  |
|
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong
Dec 02, 2024 10:34 HKT | |
|
雲頂新耀宣佈中國香港衛生署正式受理伊曲莫德（VELSIPITY(R)）
Dec 02, 2024 10:30 HKT | |
|
云顶新耀宣布中国香港卫生署正式受理伊曲莫德（VELSIPITY(R)）
Dec 02, 2024 10:25 HKT | |
|
Hua Medicine Announces Successful U.S. Phase I Results on Its 2nd Generation GKA Candidate
Nov 30, 2024 21:08 HKT |  |
|
華領醫藥宣佈成功完成在美國開展的第二代葡萄糖激酶激活劑I期臨床研究
Nov 30, 2024 20:56 HKT | |
|
华领医药宣布成功完成在美国开展的第二代葡萄糖激酶激活剂I期临床研究
Nov 30, 2024 20:46 HKT | |
|
Hua Medicine Announces Successful H.K. SENSITIZE Study Results at the CBIIC
Nov 30, 2024 20:34 HKT | |
|
華領醫藥宣佈成功完成在中國香港開展的SENSITIZE研究
Nov 30, 2024 20:11 HKT | |
|
华领医药宣布成功完成在中国香港开展的SENSITIZE研究
Nov 30, 2024 19:58 HKT | |
|
NEFECON(R) Included in National Reimbursement Drug List (NRDL)
Nov 29, 2024 10:48 HKT | |
|
耐賦康(R)納入新版國家醫保藥品目錄
Nov 29, 2024 10:45 HKT | |
|
耐赋康(R)纳入新版国家医保药品目录
Nov 29, 2024 10:42 HKT | |
|
|
<< Previous
Next >>
|